Koios Beverage (CSE:KBEV, OTC:SNOVF) (the “Company” or “Koios”), is pleased to announce that the first flavour of its new and improved line of functional cognitive enhancing beverages, Pear Guava, is now available for purchase.

Customers in both Canada and the United States can order the drink online from the company’s website https://www.mentaltitan.com/product/pear-guava/  It is also available for purchase through Koios’s large distribution network, which includes retailers such as SportLife Distribution, Max Muscle, and soon-to-be available through Amazon online.


The new formula enhances Koios’s proprietary blend of nootropics by adding super foods such as Lion’s Mane Mushroom, a powerful ingredient recognized for enhancing brain function, which Whole Foods recently listed as a trending ingredient in its annual functional ingredients guide.

“We have created the first drink of its kind,” says CEO Chris Miller, who founded the company in part because of his own personal experience with a mental-health disorder, ADHD.  The Global Brain Health market is expected to grow by a CAGR of 20 per cent to $11.6 billion by 2024, and we are excited to be innovating in the space and creating products that consumers are looking for.

“This product has taken more than four years of trial and error to ensure efficacy, and to perfect the flavour,” Miller added. “Combining those two elements is incredibly difficult and we are confident with this new line that we have delivered a product that not only tastes great, but that has incredible health benefits to the end user.”

Pear Guava is the first of the new flavours to be rolled out. It will soon be joined by Peach Mango, Blood Orange, Apricot Vanilla and Berry Genius. That will bring the product choice to five brain-healthy beverages now in production. Consumers may also purchase Koios powder that packs three times the active ingredients of the drinks per serving. The enhanced ingredients and nootropics include L-Theanine, an amino acid that has calming effects on the brain. The only caffeine used in the formula is organic, derived from Green Tea.

Koios has worked with the best food scientists in the U.S. to develop its proprietary drink formula, shown to stimulate short-term cognitive function as well as build stronger memory function over the long term. Koios uses an emulsified MCT oil as part of its proprietary blend. For that reason, the MCT oil in Koios products is better absorbed by the body. The MCT oil, instead of being metabolized through the digestion process like other fats, is taken straight to the liver where it acts in a way very similar to carbohydrates, providing instant and well sustained energy.

Koios, which began trading on the Canadian Stock Exchange at the end of April, is a leader in the exploding functional beverage market. This industry is exploding thanks to a new generation of health-conscious consumers who are demanding healthy and nutritious beverage choices in response to North America’s growing obesity epidemic.

Watch a video production of the beverage here: https://www.youtube.com/watch?v=5ZW07iX5S3c&feature=youtu.be

On behalf of the Board of Directors of the Company.
KOIOS BEVERAGE CORP.
“Chris Miller”
Chris Miller, CEO and Director

About the Company’s Business

The Company, through its wholly-owned subsidiary Koios, Inc., is an emerging functional beverage company which has a large and growing  distribution network of retail locations across the United States in which to sell its products. Koios has relationships with some of the largest and most reputable distributors in the United States, including Europa Sports, SportLife Distribution, KeHE, and Wishing-U-Well.  Together these distributors represent more than 80,000 brick-and-mortar locations across the United States – from sports nutrition stores to large natural grocery chains including Whole Foods and Sunflower markets.  Through its partnership with Wishing-U-Well, Koios also enjoys a large presence online, including being an Amazon choice product.

Koios uses a proprietary blend of nootropics and natural organic compounds to enhance human productivity without using harmful chemicals or stimulants.  Koios products can enhance focus, concentration, mental capacity, memory retention, cognitive function, alertness, brain capacity and create all day mental clarity.  Its ingredients are specifically designed to target brain function by increasing blood flow, oxygen levels and neural connections in the brain.

Koios recently launched a wholly owned subsidiary, Cannavated Beverages Co. to develop a line of cannabis infused, brain-healthy drinks for the legal marijuana market.

Koios is one of the only drinks in the world to infuse its products with MCT oil.  MCT oil is derived from coconuts and has been shown to help the body burn fat more effectively, create lasting energy from a natural food source, produce ketones in the brain, allowing for greater brain function and clarity, support healthy hormone production and improve immunity. For more information, please visit our website: https://www.mentaltitan.com/

Forward-Looking Statements

This news release contains forward-looking statements. All statements, other than statements of historical fact that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future are forward-looking statements. Forward-looking statements in this news release include statements regarding the timing for resumption of trading for the Company’s stock. The forward-looking statements reflect management’s current expectations based on information currently available and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those discussed in the forward-looking statements. Although the Company believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and, accordingly, undue reliance should not be put on such statements due to their inherent uncertainty. Factors that could cause actual results or events to differ materially from current expectations include general market conditions and other factors beyond the control of the Company. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law.
Koios has not conducted any scientific studies on the effects of Koios’s products which have been evaluated by Health Canada or the U.S. Food and Drug Administration. As each individual is different, the benefits, if any, of taking Koios’s products will vary from person to person. No claims or guarantees can be made as to the effects of Koios’s products on an individual’s health and wellbeing.

For further information: Paula Arab, Media and Investor Relations Strategist, paula.arab@koiosbeveragecorp.com, 403-889-9128

Source: www.newswire.ca

PharmaTher Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“PharmaTher”) (CSE: PHRM) and a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to provide a corporate update on its psychedelic pharmaceuticals program. Since its inception, the Company has built a unique product pipeline for novel uses of ketamine, psilocybin and undisclosed psychedelics. PharmaTher is positioning itself to partner its psilocybin program and panaceAI™, and focus on advancing its novel ketamine product pipeline in Parkinson’s disease, depression and pain via the U.S. Food and Drug Administration (“FDA”) regulatory pathway.

“We have made tremendous progress over the last several months that saw our product pipeline evolve to focus on the massive opportunity and potential of ketamine, an FDA approved drug with a known safety profile, to treat significant unmet medical needs for Parkinson’s disease, depression and pain,” said Fabio Chianelli, CEO of PharmaTher. “With our focus on ketamine through repurposing, combining it with an FDA approved drug and delivering it with our novel microneedle delivery system, we are now positioned to expedite our clinical development objectives by taking advantage of the FDA’s 505(b)(2) regulatory pathway and commercializing disruptive ketamine treatments for mental health and pain disorders.”

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN), Aurora Cannabis (NYSE: ACB)(TSX: ACB), and Canopy Growth Corporation (NASDAQ: CGC) (TSX: WEED).

Cannabis leaders are focusing on innovation in premium branding, global expansion, and tight operational execution in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders:

Keep reading... Show less

Progressive Planet Solutions Inc. (TSXV: PLAN) (“PLAN” or “Progressive Planet”), an emerging leader in reducing the carbon footprint of cement products using natural pozzolans, is pleased to announce it has sold and optioned a combined total of 10 million of its 10.5 million shares of Snow Lake Resources.

The sale and option agreements were made with two arms-length purchasers. The first sale was for 1,700,000 shares at $0.04 per share for a total of $68,000 and includes an option granted by PLAN entitling the same party to purchase an additional 4,966,666 shares at $0.04 per share until May 11, 2021 . The second sale was for 1,250,000 shares at $0.04 per share for a total of $50,000 and includes an option granted by PLAN to such party to purchase an additional 2,083,334 shares until August 14, 2021 . As at the date of this news release, PLAN has received $116,000 and will receive another $284,000 if the remaining shares are purchased under the option agreements.

Keep reading... Show less

First Products to Hit California Shelves in Q2 2021

 4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) is pleased to announce that its fully funded state of the art 185,000 square foot production facility in Commerce, California is nearing completion and will be ready to serve the $3b California cannabis market in Q2 2021. The project is on target to be completed in April 2021 with the Company planning for the first of its full line of edibles, tinctures and vape products to be on California retail shelves by May.

Keep reading... Show less

MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the “Company”, “MustGrow”) is pleased to announce its upcoming investor awareness initiatives. MustGrow continues to actively engage its key stakeholders – potential industry partners, shareholders and prospective investors – by increasing awareness of its remarkable natural mustard-derived crop protection products.

TODAY: The Future of Food Investment Conference – SnowCap Ventures
Tuesday, Nov. 24th at 1:50 pm ET
Investors Register Here

Keep reading... Show less